Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lerner

Showing results (321-330 of 375) with videos related to

Pageof 38
Sort By:
Alzheimer'S & Dementia (New York, N. Y.)|August 4, 2023
Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 studyEmily D Clark, Jamie Perin, Nathan Herrmann, et al.
International Psychogeriatrics|September 19, 2024
Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2Shankar Tumati, Nathan Herrmann, Jaime Perin, et al.
International Psychogeriatrics|January 31, 2025
Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2Shankar Tumati, Nathan Herrmann, Jaime Perin, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|May 29, 2020
Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With MethylphenidateChristopher H van Dyck, Amy F T Arnsten, Prasad R Padala, et al.
JAMA Neurology|September 27, 2021
Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical TrialJacobo Mintzer, Krista L Lanctôt, Roberta W Scherer, et al.
International Journal of Geriatric Psychiatry|June 10, 2024
Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)Lijuan Zeng, Jamie Perin, Alden L Gross, et al.
Pacing and Clinical Electrophysiology : PACE|October 15, 2010
Implantation success and infection in cardiovascular implantable electronic device procedures utilizing an antibacterial envelopeHeather L Bloom, Luis Constantin, Daniel Dan, et al.
American Journal of Human Genetics|January 16, 2002
Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouseHanlin Gao, Rose-Mary N Boustany, Janice A Espinola, et al.
Neurology|July 12, 2015
Improving clinical cognitive testing: report of the AAN Behavioral Neurology Section WorkgroupKirk R Daffner, Seth A Gale, A M Barrett, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|June 23, 2020
Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of InstrumentsKrista L Lanctôt, Roberta W Scherer, Abby Li, et al.
Pageof 38

Showing results (321-330 of 375) with videos related to

Sort By:
Pageof 38
Alzheimer'S & Dementia (New York, N. Y.)|August 4, 2023
Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 studyEmily D Clark, Jamie Perin, Nathan Herrmann, et al.
International Psychogeriatrics|September 19, 2024
Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2Shankar Tumati, Nathan Herrmann, Jaime Perin, et al.
International Psychogeriatrics|January 31, 2025
Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2Shankar Tumati, Nathan Herrmann, Jaime Perin, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|May 29, 2020
Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With MethylphenidateChristopher H van Dyck, Amy F T Arnsten, Prasad R Padala, et al.
JAMA Neurology|September 27, 2021
Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical TrialJacobo Mintzer, Krista L Lanctôt, Roberta W Scherer, et al.
International Journal of Geriatric Psychiatry|June 10, 2024
Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)Lijuan Zeng, Jamie Perin, Alden L Gross, et al.
Pacing and Clinical Electrophysiology : PACE|October 15, 2010
Implantation success and infection in cardiovascular implantable electronic device procedures utilizing an antibacterial envelopeHeather L Bloom, Luis Constantin, Daniel Dan, et al.
American Journal of Human Genetics|January 16, 2002
Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouseHanlin Gao, Rose-Mary N Boustany, Janice A Espinola, et al.
Neurology|July 12, 2015
Improving clinical cognitive testing: report of the AAN Behavioral Neurology Section WorkgroupKirk R Daffner, Seth A Gale, A M Barrett, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|June 23, 2020
Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of InstrumentsKrista L Lanctôt, Roberta W Scherer, Abby Li, et al.
Pageof 38